about
Lipidomic Analysis of Endocannabinoid Signaling: Targeted Metabolite Identification and QuantificationProstanoid receptor antagonists: development strategies and therapeutic applicationsSubstrate-selective COX-2 inhibition as a novel strategy for therapeutic endocannabinoid augmentationBimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial.Prostamides (prostaglandin-ethanolamides) and their pharmacology.Late-day intraocular pressure-lowering efficacy and tolerability of travoprost 0.004% versus bimatoprost 0.01% in patients with open-angle glaucoma or ocular hypertension: a randomized trial.Bimatoprost 0.03% for the Treatment of Eyelash Hypotrichosis: A Pooled Safety Analysis of Six Randomized, Double-masked Clinical TrialsClinical pharmacology of bimatoprost.Fixed-combination and emerging glaucoma therapies.Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain.Bimatoprost 0.03% preservative-free ophthalmic solution versus bimatoprost 0.03% ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: a 12-week, randomised, double-masked trialAnandamide-derived prostamide F2α negatively regulates adipogenesisBimatoprost, prostamide activity, and conventional drainage.Gastrointestinal endocannabinoid system: multifaceted roles in the healthy and inflamed intestine.Twenty-four-hour effects of bimatoprost 0.01% monotherapy on intraocular pressure and ocular perfusion pressureEffect of preservative removal from fixed-combination bimatoprost/timolol on intraocular pressure lowering: a potential timolol dose-response phenomenonIdentification of an antagonist that selectively blocks the activity of prostamides (prostaglandin-ethanolamides) in the feline iris.In vivo comparative study of ocular vasodilation, a relative indicator of hyperemia, in guinea pigs following treatment with bimatoprost ophthalmic solutions 0.01% and 0.03%.Corneal neovascularization and ocular irritancy responses in dogs following topical ocular administration of an EP4-prostaglandin E2 agonist.A novel convergent synthesis of the antiglaucoma PGF2α analogue bimatoprost.
P2860
Q26769959-389A4CE9-87CF-4934-819B-153BE9412890Q33485483-B464883A-9000-44D5-AA1D-7AB621361B38Q33819279-ABB0C6FA-7286-4BC7-9E41-36127AE8FB35Q33834484-3DA071B8-9560-42CF-9DF0-5377A1DDD9F2Q34667670-4BC67079-95AA-4D68-A661-AC1261033D47Q34981213-003CA4ED-6C9F-4C37-9C17-C19F9EF69D30Q35871898-65C915A5-15A6-4410-A8FD-7D786C860480Q36572646-641D7512-EB50-4F3F-A15E-E344F4CCC309Q36866626-0D7E19B3-4A1E-4FD8-85D2-13B88C0B4B37Q36912778-85A6427B-F337-4056-978E-D0939BEBE0A5Q37030839-7FFFAC73-EDE8-4B70-8B67-8565DF63CF05Q37095444-764DD3E5-7D64-49B9-83D0-2E00191E09A8Q37187695-7F90AC8C-4754-42D3-97BB-500C0C26C595Q37232058-11C886F9-322A-46F8-8E9F-49F194B50D73Q37634184-83039DCB-27B6-4DF6-92F7-D6AF604294B2Q38797407-8D3E6186-3772-438A-9918-DEDBC71A5B3BQ41585257-AC598023-9E5B-41EE-AF15-E6BE3589606FQ42581183-74D54347-E40E-4A0E-B52F-8AB6C866A55FQ43222813-5252702A-5FAC-494B-BE77-2712667B232DQ44637557-5B9731B9-68DC-4A92-ABDB-35771482642E
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Bimatoprost: a novel antiglaucoma agent.
@ast
Bimatoprost: a novel antiglaucoma agent.
@en
type
label
Bimatoprost: a novel antiglaucoma agent.
@ast
Bimatoprost: a novel antiglaucoma agent.
@en
prefLabel
Bimatoprost: a novel antiglaucoma agent.
@ast
Bimatoprost: a novel antiglaucoma agent.
@en
P2093
P2860
P1476
Bimatoprost: a novel antiglaucoma agent.
@en
P2093
A H-P Krauss
David F Woodward
L A Wheeler
R L Phelps
P2860
P304
P356
10.1111/J.1527-3466.2004.TB00134.X
P577
2004-01-01T00:00:00Z